Key Stats | |
---|---|
Open | $217.20 |
Prev. Close | $216.94 |
EPS | 6.51 |
Dividend | $1.92 |
Next Earnings Date | Sep 12, 2024 |
Dividend Yield % | 0.89% |
Market Cap | $31.87B |
PE Ratio | 33.20 |
LOW | HIGH | |
---|---|---|
Day Range | 215.71 | 217.24 |
52 Week Range | 132.24 | 237.25 |
Ratios | |
---|---|
P/B Ratio | 6.10 |
Revenue | $4.22B |
Operating M. % | 31.29% |
Earnings | $897.55M |
Earnings Growth % | 15.15% |
EBITDA Margin % | 34.13% |
ROE % | 22.39% |
EPS | 6.51 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
All Score 77 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
RMD | MARKET | |
---|---|---|
Value | 35 | 38 |
Quality | 87 | 40 |
Ownership | 26 | 17 |
Growth | 60 | 44 |
Dividends | 28 | 37 |
ResMed 's Price growth average in the last 3 years of 4.51% is modest compared to market average of 6.39%. This indicates RMD could be a bad value stock.
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
The current price per share for ResMed (RMD) is $216.16. The stock has seen a price change of -$0.78 recently, indicating a -0.36% change. This reflects the stock's recent market performance and investor sentiment.
For ResMed (RMD), the 52-week high is $237.26, which is 9.76% from the current price. The 52-week low is $132.24, the current price is 63.46% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
ResMed (RMD) has shown an average price growth of 0.41% over the past three years. It has received a score of 48 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying ResMed as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
As of the latest data, ResMed (RMD) has a year-to-date price change of 25.84%. Over the past month, the stock has experienced a price change of 15.13%. Over the last three months, the change has been 13.34%. Over the past six months, the figure is 40.47%. Looking at a longer horizon, the five-year price change stands at 91.92%.
ResMed (RMD) has a net income of $897.56M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 55.78% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 31.29% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $4.22B, with a revenue growth rate of 18.02%, providing insight into the company's sales performance and growth. The gross profit is $2.36B. Operating income is noted at $1.13B. Furthermore, the EBITDA is $1.56B.
ResMed (RMD) has a market capitalization of $31.88B. The average daily trading volume is 1.48M, indicating the stock's liquidity and investor engagement.
Visa’s Quarterly Revenue Jumped by $800 Million YoY and Hit an All-Time High of $8.75 Billion
Samsung Overtakes Apple in Q1 2024 Mobile Phone Shipments with 20.8% Market Share
Financial Industry Plagued by Ransomware Attacks; 65% of Organizations Suffered Ransomware Damage in 2023
GPU Prices: H100 Resellers Raking in Over 3X Profits on Popular Online Marketplaces
Analysts Bullish on AI Stocks Beyond Nvidia: SoundHound AI, Baidu, and UiPath Offer Up to 60% Upside Potential
Almost 50% of Americans Support Potential TikTok Ban
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.